Title:
ＧＩＰ／ＧＬＰ１共アゴニスト化合物
Document Type and Number:
Japanese Patent JP6920559
Kind Code:
B2
Abstract:
The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
More Like This:
Inventors:
Abraham, Mirata Mary
Aburub, Akkamu
Arcina-Fernandez, Giorgi
Brown, Robert Andrew
Cabrera, over
Koscoon, Tamar
Cummins, Robert Chadwick
Datta-Mannan, Amita
Elsade, Mohamed Elsade Hamed
Lai, Shen Inn
Patel, Phenyl Jayantiral
Chu, Hong Chang
Sloop, Kyle Win
Trang, Titan Huen
Wallis, James Lincoln
Willard, Francis Stafford
Aburub, Akkamu
Arcina-Fernandez, Giorgi
Brown, Robert Andrew
Cabrera, over
Koscoon, Tamar
Cummins, Robert Chadwick
Datta-Mannan, Amita
Elsade, Mohamed Elsade Hamed
Lai, Shen Inn
Patel, Phenyl Jayantiral
Chu, Hong Chang
Sloop, Kyle Win
Trang, Titan Huen
Wallis, James Lincoln
Willard, Francis Stafford
Application Number:
JP2020545276A
Publication Date:
August 18, 2021
Filing Date:
July 22, 2019
Export Citation:
Assignee:
Eli Lilly and Company
International Classes:
C07K14/605; A61K9/14; A61K9/20; A61K9/22; A61K9/48; A61K9/52; A61K38/26; A61K38/55; A61K47/12; A61K47/18; A61K47/24; A61K47/26; A61K47/28; A61P1/16; A61P3/00; A61P3/04; A61P3/06; A61P3/10
Domestic Patent References:
| JP2017507124A | ||||
| JP2015517459A |
Foreign References:
| US20170112897 | ||||
| WO2014049610A1 |
Attorney, Agent or Firm:
Hiroshi Kobayashi
Norio Omori
Inori Toshihiro
Yasuhito Suzuki
Norio Omori
Inori Toshihiro
Yasuhito Suzuki